We are building an unprecedented pipeline of synergistic genomic medicines in the ocular space to bring relief to inherited retinal disease patients.
Our Portfolio from 2022
SPVN06
SparingVision’s lead product, SPVN06, is a breakthrough gene therapy approach targeting Inherited Retinal Diseases (IRDs).
Learn More
PARTNERS
